Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?

Scand J Gastroenterol Suppl. 1988;143:81-5. doi: 10.3109/00365528809090223.


We report the development of ceftazidime-resistant strains of Pseudomonas aeruginosa in a small population of cystic fibrosis patients who had ceftazidime monotherapy over a 5-year period as clinically indicated. The background rate of less than 30% of patients with a ceftazidime-resistant strain of P. aeruginosa in their sputum each month is similar to the resistance rate to other anti-pseudomonas antibiotics that have seldom been used here. In practice this resistance has meant that for about 10% of patients each month consideration has to be given to the use of an agent other than ceftazidime.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ceftazidime / therapeutic use*
  • Cystic Fibrosis / complications*
  • Drug Resistance, Microbial
  • Follow-Up Studies
  • Humans
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / etiology
  • Pseudomonas aeruginosa / drug effects*
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / etiology
  • Time Factors


  • Ceftazidime